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Abstract
Background: In the UK, macular laser is the treatment of choice for people with diabetic macular oedema with
central retinal subfield thickness (CST) < 400 μm, as per National Institute for Health and Care Excellence guidelines.
It remains unclear whether subthreshold micropulse laser is superior and should replace standard threshold laser for
the treatment of eligible patients.
Methods: DIAMONDS is a pragmatic, multicentre, allocation-concealed, randomised, equivalence, double-masked
clinical trial that aims to determine the clinical effectiveness and cost-effectiveness of subthreshold micropulse laser
compared with standard threshold laser, for the treatment of diabetic macular oedema with CST < 400 μm. The
primary outcome is the mean change in best-corrected visual acuity in the study eye from baseline to month 24
post treatment. Secondary outcomes (at 24 months) include change in binocular best corrected visual acuity; CST;
mean deviation of the Humphrey 10–2 visual field; change in percentage of people meeting driving standards;
European Quality of Life-5 Dimensions, National Eye Institute Visual Functioning Questionnaire-25 and VisQoL
scores; incremental cost per quality-adjusted life year gained; side effects; number of laser treatments and use of
additional therapies.
The primary statistical analysis will be per protocol rather than intention-to-treat analysis because the latter increases
type I error in non-inferiority or equivalence trials. The difference between lasers for change in best-corrected visual
acuity (using 95% CI) will be compared to the permitted maximum difference of five Early Treatment Diabetic
Retinopathy Study (ETDRS) letters. Linear and logistic regression models will be used to compare outcomes between
treatment groups. A Markov-model-based cost-utility analysis will extend beyond the trial period to estimate longer-
term cost-effectiveness.
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Discussion: This trial will determine the clinical effectiveness and cost-effectiveness of subthreshold micropulse laser,
when compared with standard threshold laser, for the treatment of diabetic macular oedema, the main cause of sight
loss in people with diabetes mellitus.
Trial registration: International Standard Randomised Controlled Trials, ISRCTN17742985. Registered on 19 May 2017
(retrospectively registered).
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Background
Diabetic macular oedema (DMO) is a leading cause of
blindness in people with diabetes mellitus. It represents
the accumulation of fluid at the macula, the area of the
retina responsible for central vision. As fluid accumu-
lates, visual loss ensues. Macular laser was, until recently,
the treatment of choice for people with DMO. The Early
Treatment Diabetic Retinopathy Study (ETDRS) demon-
strated the beneficial effects of laser in 1985 [1]. The
ETDRS showed that macular laser reduced the risk of vis-
ual loss (loss of ≥ 3 lines) in patients with clinically signifi-
cant diabetic macular oedema (CSMO) by 50% at 3 years
[1]. Only a few patients (3%) experienced visual acuity im-
provement of ≥ 15 letters but 85% of the eyes studied had
vision of ≥ 20/40 at baseline, which could have accounted
for the limited visual improvement observed [1]. More re-
cent trials have shown higher rates of visual improvement
(≥ 10 letters in 32% of patients at 2 years and in 44% at 3
years) [2, 3] suggesting that macular laser can indeed im-
prove vision.
Anti-vascular endothelial growth factor (anti-VEGF)
therapies may be an alternative to laser treatment. The
National Institute for Health and Care Excellence
(NICE) in the UK reviewed ranibizumab (Lucentis®) and
aflibercept (Eylea®) for the treatment of DMO, in 2013
(TA274) and 2015 (TA346), respectively [4, 5].NICE
concluded these therapies were superior to macular laser
for people with central retinal thickness ≥ 400 μm
(CRT), as determined by spectral domain optical coher-
ence tomography (SD-OCT), and, thus, recommended
these drugs for this group of patients. However, for
people with CRT < 400 μm, the cost-effectiveness evalu-
ation showed laser treatment dominated and, hence, it
remains the treatment of choice in the latter group. The
NICE appraisal of ranibizumab in DMO used data from
the RESTORE study, in which subgroups were
pre-specified by retinal thickness < 300 μm, 300–400
and > 400. There was no significant difference between
ranibizumab and laser in the < 300 μm group, but ranibi-
zumab was much more effective than laser in the > 400
group, in which there was no improvement in best cor-
rected visual acuity (BCVA) with laser. In the intermedi-
ate 300–400 μm group, ranibizumab was somewhat
more effective than laser, with gains of ~ 8 and 4 letters
in the ranibizumab and laser groups, respectively; the
difference was statistically significant but of no clinical
relevance. The much higher cost of ranibizumab meant
that the cost per quality-adjusted life year (QALY) was
very high and NICE did not consider ranibizumab to be
cost-effective in the < 400 groups. Interestingly, in recent
clinical trials comparing ranibizumab and aflibercept
with laser, the mean CRT on average was > 400 μm
(405 μ DRCR.net protocol I; > 460 μ RISE and RIDE;
412–426 μ RESTORE; > 479 μ VISTA and VIVID) [6–9].
Macular laser is also used in patients with DMO who do
not fully respond to anti-VEGF therapy; in randomised
trials, 41–64% of the eyes studied receiving anti-VEGF
therapy required macular laser by 2 years after start of
treatment [10].
Standard threshold macular laser is performed using a
continuous wave laser that produces a visible burn in the
retina. The laser energy is predominantly absorbed by one
of the layers of the retina, the retinal pigment epithelium
(RPE), and converted into heat. Although the mechanisms
of action of conventional threshold laser are not com-
pletely understood, it is believed that it acts upon still-vi-
able RPE cells around the site of the burn. As heat spreads
by conduction, there is a potential for damage to the ret-
inal layers overlying the RPE, including the photoreceptors
(light-sensitive cells). Standard laser requires considerable
expertise by the clinician who needs to identify, by
slit-lamp biomicroscopy and with the help of SD-OCT
and fundus fluorescein angiography (FFA), areas involved
at which the laser should be aimed. Side effects of stand-
ard threshold macular laser are rare but include paracen-
tral scotomas (areas around the central vision in which
patients do not see, which may affect reading and driving),
reduced colour vision and epiretinal membrane/subretinal
fibrosis. If the centre of the macula is accidentally treated
with laser (foveal burn), this will likely result in marked
visual loss. If strong laser is applied close to the centre of
the macula, subsequent atrophy (which could expand over
the years to the centre) could similarly lead to loss of cen-
tral vision.
Unlike in standard threshold laser, in subthreshold
micropulse laser a series of repetitive very short laser
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pulses are applied. Each pulse is separated by a long
off-time, which reduces the increased temperature in the
tissue that follows conventional laser; a sublethal effect
on the RPE is achieved with preservation of the overly-
ing neurosensory retina, including the photoreceptors.
Small case series and randomised trials including small
numbers of patients have shown that subthreshold
micropulse laser may be comparable or more efficacious
than standard laser, with reduced side effects. For ex-
ample, Lavinsky and collaborators, showed the superiority
of high-density subthreshold micropulse laser in visual acu-
ity improvement and reduced CRT at 12months in a trial
of participants randomised to this treatment (n = 42), to
standard threshold laser (n = 42) or to low-density sub-
threshold micropulse laser (n = 39) [11]. In another trial in-
cluding 50 patients with DMO, Vujosevic and colleagues
found no differences in vision or CRT between patients
randomised to standard threshold laser or subthreshold
micropulse laser, but there was statistically significantly in-
creased retinal sensitivity on microperimetry following the
latter, with no laser scars in the retina at 12-month follow
up [12]. Randomised trials by Kumar and associates, [13]
Figueira and coworkers [14] and Laursen and collaborators
[15] including 20, 53 and 16 patients, respectively, and with
follow up of 18 weeks, 12months and 5months, respect-
ively, found no differences in vison and CRT between the
two types of laser. A recently published review [16] con-
cluded that the available data suggests that subthreshold
micropulse laser has similar or superior efficacy to standard
threshold laser, with less or with no retinal damage. Sub-
threshold micropulse laser may allow also for more stan-
dardised delivery of treatment, given that it is applied to the
entire macular area in a confluent manner, it reduces/mini-
mises possible variability and is less dependent on the sur-
geon’s skills. Sight loss as a result of a foveal burn is
obviated if subthreshold micropulse laser is used.
In summary, the published data suggest that sub-
threshold micropulse laser may be superior to conven-
tional threshold laser, but stronger evidence is required
to determine whether this is the case and whether this
form of laser should be used instead of conventional
threshold laser for the treatment of DMO.
Subjects and methods
Ethical approval for this study was granted by the Office
for Research Ethics Committees Northern Ireland (REC
Reference 16/NI/0145).
Study design and setting
DIAMONDS is a pragmatic, multicentre, allocation-con-
cealed, randomised, equivalence, double-masked clinical
trial set within specialised Hospital Eye Services (HES) in
the UK (see list of participating centres below). It aims to
evaluate the clinical effectiveness and cost-effectiveness of
subthreshold micropulse laser, when compared with
standard threshold laser, for the treatment of patients with
DMO with CST < 400 μm.
Participants: eligibility criteria
Potential study participants will be identified through
patient electronic databases at each participating
centre, through referrals to HES or while in the clinic.
Patients identified through electronic databases or re-
ferrals will be approached by phone or via an invita-
tion letter. Verbal and written information about the
study will be given to the participant and informed
consent will be sought at their next clinical appoint-
ment; if provided, the patient will be recruited into the
study. Patients identified while in clinic will be ver-
bally informed about the study and they will receive a
patient information leaflet. They will be given time to
think about their participation and ask questions
about the study. If they wish to go ahead and be en-
rolled on the same day, they will be recruited into the
trial following informed consent. If someone would
like more time to think about their potential participa-
tion in the study, a further visit will be organised for
them. If, at this visit, they are willing to participate,
they will be recruited.
Informed consent to participate in the study will be ob-
tained by the ophthalmologist or a designee at each par-
ticipating site. The treating ophthalmologist will obtain
informed consent to carry out the laser procedure(s).
Inclusion criteria
Eligible participants will have DMO at the centre of the
macula, as determined by slit-lamp biomicroscopy and
SD-OCT, in one or both eyes with either:
1. CST of > 300 but < 400 microns as determined by
SD-OCT due to DMO or
2. CST of < 300 microns provided that intraretinal
and/or subretinal fluid is present in the central
subfield (central 1 mm) related to DMO
They will also:
1. Have visual acuity of > 24 Early Treatment Diabetic
Retinopathy Study (ETDRS) letters (Snellen
equivalent > 20/320)
2. Be amenable to laser treatment, as judged by the
treating ophthalmologist
3. Be over 18 years of age
Exclusion criteria
The participants’ eyes will not be eligible for the study if
the macular oedema is due to causes other than DMO
or if the eye is:
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1. Ineligible for macular laser treatment, as judged by
the treating ophthalmologist
2. Has DMO and CST of 400 μm or above
3. Has active proliferative diabetic retinopathy (PDR)
requiring treatment
4. Has received intravitreal anti-VEGF therapy within
the previous 2 months
5. Has received macular laser treatment within the
previous 12 months
6. Has received intravitreal injection of steroids
7. Has had cataract surgery within the previous 6
weeks
8. Has had panretinal photocoagulation (PRP) within
the previous 3 months
Otherwise eligible patients will not be included in the
study if they:
1. Are on pioglitazone (as this drug could potentially
be responsible for the presence of macular oedema)
and the drug cannot be stopped 3months prior to
entering into the trial and for the duration of the
study
2. Have chronic renal failure requiring dialysis or
kidney transplant
3. Have any other condition that in the opinion of
the investigator would preclude participation in
the study (such as unstable medical status or
severe disease that would make it difficult for the
patient to be able to complete the study)
4. Have very poor glycemic control that required
starting intensive therapy within the previous 3
months
5. Are using an investigational drug
If both eyes are eligible, both will receive the same
type of laser but one will be designated the ‘study eye’.
This will be the eye with best visual acuity at random-
isation or, if vision is the same in both eyes, the eye
with lesser CST.
If the fellow eye is not eligible, baseline data and
information on whether participants develop DMO
or PDR during the period of the study in the fellow
eye and on treatments administered to it will be col-
lected in the case report form (CRF) at months 12
and 24, to determine any possible effects of these
events on outcomes.
Outcome measures
Primary outcome
 Mean change in BCVA in the study eye at 24months
following treatment
Secondary outcomes
 Mean change in binocular best-corrected distance
visual acuity (BCdVA) from baseline to month 24
 Mean change in CST in the study eye, as
determined by SD-OCT, from baseline to month 24
 Mean change in the mean deviation (MD) of the
Humphrey 10–2 visual field in the study eye from
baseline to month 24
 Change in the percentage (%) of people meeting UK
driving standards from baseline to month 24
 Mean change in EuroQoL(EQ-5D 5 L), the National
Eye Institute Visual Function Questionnaire (NEI
VFQ25) and VisQoL scores from baseline to
month 24
 Incremental cost per QALY gained
 Side effects
 Number of laser treatments performed
 Use of additional treatments (other than laser)
Potential participants will be identified through referrals
to participating HES or in ophthalmic clinics. Verbal and
written information about the study will be provided. In-
formed consent will be obtained by the local principal in-
vestigator or designee at each site from those willing to
participate. The schedule of visits and tests undertaken in
DIAMONDS follows routine clinical practice; this should
facilitate recruitment and retention of participants in the
trial. In order to ensure adequate attendance of partici-
pants to follow-up visits, participants will be reminded by
telephone, text or call the week prior to the study visit.
This will be carried out by either research nurses or by ad-
ministrative staff at each of the participating centres.
Randomisation, interventions and study procedures
Randomisation
Participants will be randomised 1:1 using an auto-
mated randomisation system to receive either sub-
threshold micropulse laser (577 nm) or standard
threshold laser, with the allocation concealed to the
ophthalmologist randomising the patient until the pa-
tient has joined the trial. The local ophthalmologist
will interact with this automated system to ensure
masking of the outcome assessors to the allocation
after randomisation. Although it is envisaged that
most patients will receive laser at the baseline visit,
laser can be performed within 2 weeks of that visit. If
there is an interval between the baseline visit and the
laser treatment, eligibility will be re-confirmed prior
to undertaking the laser. Randomisation is advised to
be conducted on the day of laser treatment.
The randomisation system will use a minimisation algo-
rithm to ensure balanced allocation of patients across
treatment groups for the following important prognostic
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factors: centre, distance BCdVA at presentation [≥ 69
ETDRS letters (Snellen equivalent ≥ 20/40; Logarithm of
the Minimum Angle of Resolution (logMAR) ≥ 0.3); 24–
68 ETDRS letters (Snellen equivalent ≤ 2 0/50; logMAR
0.4–1.2)], previous use of anti-VEGFs or macular laser in
the study eye.
Intervention: laser treatment strategy and retreatments
Standard laser will be applied to areas of thickened ret-
ina, macular non-perfusion (away from and non-con-
tiguous with the perifoveal capillaries) and leaking
microaneurysms, in accordance with the Royal College
of Ophthalmologist guidelines [17]. FFA and OCT will
be used to identify areas of non-perfusion and leakage
(FFA) and thickening (OCT) prior to treatment at the
discretion of the treating ophthalmologist. Treatment
will be applied to obtain a mild grey-white burn evident
beneath leaking microaneurysms and in other areas of
leakage/non perfusion not affecting the perifoveal capil-
laries based on FFA, if FFA has been obtained, and/or to
cover areas of thickening if treatment is given based on
OCT findings. Treatment will spare the central 500 μm
and the area within 500 μm from the optic nerve head.
The majority of prospective, randomised controlled
clinical trials on micropulse subthreshold laser therapy
for the treatment of DMO have been performed with
the 810 nm infrared diode laser [11, 12, 14, 15, 18].
Available data suggest similar efficacy and safety be-
tween 810 nm and 577 nm micropulse laser therapy
for DMO [19, 20]. In DIAMONDS, micropulse laser
therapy will be delivered with a 577 nm optically
pumped diode laser (IQ 577™ laser system; IRIDEX
Corporation). Subthreshold micropulse laser will be ap-
plied confluently to the macular area, using three 7 × 7
spot grids above and below the fovea (500 μm from its
centre) and one 7 × 7 spot grid at each side (temporal and
nasal) of the fovea (500 μm from its centre); treatment will
also be applied to areas of thickening located outside this
central area. First, a threshold will be set by titrating the
power of the laser upwards, starting from 50mW, in 10
mW increments, in an area where oedema is present,
around > 2 DD (disc diameters) from foveal center (if pos-
sible), and until a barely visible tissue reaction is seen. If a
reaction is evident with 50mW, the power will not be in-
creased. Then, the laser will be turned into the micropulse
mode; on micropulse, the power of the laser will be set at
× 4 the threshold identified (e.g. if a barely visible reaction
is seen at 50mW, then micropulse laser will be applied
with 200mW power).
Application of standard threshold and micropulse
subthreshold laser will follow the DIAMONDS guide-
lines set for this purpose. All details of the laser proce-
dure(s) will be recorded in an appropriately designed
CRF including, among other details, the eye to be
treated, the type of laser and laser parameters used, the
name and grade of the physician conducting the treat-
ment and the time spent applying the treatment.
Retreatments with laser can and should be undertaken,
if necessary. All retreatments should use the same laser
as determined by randomisation. The treatment of areas
within 300–500 μm from the centre of the fovea is
allowed when retreating. Details of retreatments should
be documented in the case report form (CRF).
Rescue treatment (with anti-VEGFs or steroids as ap-
propriate) will be allowed in both treatment groups if
the CST increases to 400 μm or over at any point during
the follow up or if a loss ≥ 10 ETDRS letters occurs re-
lated to DMO. Rescue treatments will be recorded (type
and date) in the CRF.
Study procedures: patient evaluation
All patients will be evaluated during the study according
to the schedule of assessments shown in Table 1. BCVA
will be measured in both eyes using ETDRS visual acuity
charts at 4 m at baseline and at months 4, 8, 12, 16, 20
and 24. BCVA will be obtained following refraction at
baseline, 12 and 24months by optometrists masked to
treatment allocation. At all other visits, BCVA could be
obtained by other masked staff using the most recently
obtained refraction. Binocular BCVA will be obtained
also to give indication of the person’s vision in real life,
using both eyes; it will be obtained by masked optome-
trists using the ETDRS visual acuity charts at 4 m at
baseline and 12 and 24months. A refraction protocol (as
set in the DIAMONDS Visual Acuity Guideline con-
tained in the Trial Manual) will be followed by the DIA-
MONDS optometrists to obtain BCVA. ETDRS visual
acuity scores will be recorded for study eyes and fellow
eyes in the appropriate CRF at each study visit.
The study eye or both eyes (if both are included) will
undergo 10–2 Humphrey visual field testing by a visual
field technician masked to the allocated treatment at
baseline and at months 12 and 24. The Esterman bin-
ocular visual field (to determine patient’s ability to fulfil
driving standards) will be obtained at the same time
points. Visual fields eligible for analysis will have to
achieve pre-defined reliability criteria (false positives <
15%). If the visual fields are not reliable they should be
repeated. The mean deviation (MD) value for the 10–2
Humphrey visual fields and the number of points seen/
missed in the Esterman binocular visual fields will be re-
corded in the CRF.
CST, as determined by using SD-OCT, will be ob-
tained in both eyes at baseline and at months 4, 8, 12,
16, 20 and 24. SD-OCT will be obtained by technicians,
photographers or nurses, as per standard clinical prac-
tice at each of the participating centres, masked to the
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treatment allocation. The measure of thickness at the
central 1 mm (i.e. CST) will be recorded in the CRF and
used for analysis. In addition, total and maximal macular
volume, will be recorded in the CRF. Presence or absence
of intraretinal or subretinal fluid will be determined in a
masked fashion by masked readers at the Central Angio-
graphic Resource Facility (CARF) at Queens University,
Belfast at the 24-month follow-up visit. Images sent to
CARF will be anonymised. The same SD-OCT machine
should be used to obtain the above measurement for each
patient at baseline and at each of the follow-up visits.
We will use two vision-related quality of life tools:
the NEI VFQ-25 and the VisQol questionnaires. We
will also use the generic preference-based health-re-
lated quality of life measure EQ-5D-5 L to generate util-
ity data. All questionnaires will be self-completed by
patients at baseline and at 12 and 24 months. The base-
line questionnaires should be completed before the first
session of laser treatment (subthreshold micropulse or
threshold standard laser).
As stated previously, outcome assessors and also par-
ticipants will be masked to the treatment allocation. Par-
ticipants will be followed at 4-month intervals following
laser for a total of seven visits, which is in accordance
with routine standard clinical care. Additional visits (in-
terim visits) may occur, if required.
In order to maximise retention in the study, DIA-
MONDS was designed as a pragmatic trial, with visits every
4months, as stated previously, as in usual, routine care. In
most visits, with the exception of those at baseline, 12 and
24months, the tests will be the same as those done in rou-
tine practice (i.e. measure of visual acuity and SD-OCT
scans). Furthermore, participants will be reminded of their
clinical appointment by telephone, text or call a week be-
fore the study visit.
A CONSORT diagram will be presented for the study,
as shown in Fig. 1.
Data collection and quality checks
CRFs will be used to collect data for the trial. On-site
monitoring visits during the trial will check the accur-
acy of entries in the CRF against the source documents,
the adherence to the protocol, procedures and to the
International Conference of Harmonisation Good Clin-
ical Practice (ICH-GCP) guidelines and regulatory re-
quirements. Monitoring visits will be undertaken by a
monitor from the Northern Ireland Clinical Trials Unit
(NICTU). To ensure accurate, complete and reliable
data are collected, the Chief Investigator and the
NICTU will provide training to site staff through inves-
tigator meetings and site initiation visits.
Data quality control checks will be carried out by a data
manager following standard operating procedures set at the
NICTU, to ensure accuracy, and data errors will be docu-
mented in quality control reports with corrective actions
implemented. Data validation will be implemented and
Table 1 Schedule of assessments and procedures
Baselineb Post randomisation (months)
4b 8b 12b 16b 20b 24b
Informed consent ✓
Medical history ✓ ✓ ✓ ✓ ✓ ✓ ✓
HbA1ca ✓
BCVA in study eye and fellow eye ✓ ✓ ✓ ✓ ✓ ✓ ✓
Binocular distance vision ✓ ✓ ✓
Humphrey 10–2 visual field in study eye ✓ ✓ ✓
Esterman binocular visual field ✓ ✓ ✓
SD-OCT ✓ ✓ ✓ ✓ ✓ ✓ ✓
NEI VFQ-25 ✓ ✓ ✓
EQ-5D-5L ✓ ✓ ✓
VisQol ✓ ✓ ✓
Randomisation ✓
Subthreshold micropulse laser/
standard threshold laser
✓ $ $ $ $ $ $
Adverse events ✓ ✓ ✓ ✓ ✓ ✓ ✓
BCVA best corrected visual acuity, SD-OCT spectral domain optical coherence tomography, NEI-VFQ-25 National Eye Institute Visual Functioning Questionnaire-25,
EQ-5D-5 L European Quality of Life-5 Dimensions, $ retreatment is possible at follow-up visits if needed
aIf glycosylated haemoglobin type A1C (HbA1c) has been tested in the past 3 months and its value is available, it can be recorded in the case report form. If no
previous HBA1c test (within the previous 3 months from baseline), a blood sample should be drawn to measure it. HbA1c is obtained as a measure of
glycaemic control
bVisits may take place within ± 14 days of the due date
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discrepancy reports will be generated following data entry
to identify discrepancies such as out of range, inconsisten-
cies or protocol deviations based on data validation checks
programmed in the clinical trial database.
Data obtained in DIAMONDS will be made available
to the scientific community with as few restrictions as
possible; the DIAMONDS group, however, will retain
exclusive use until the major outputs have been pub-
lished. Anonymised data will be deposited in the DIA-
MONDS website.
Sample size
DIAMONDS is powered to demonstrate non-inferiority
of subthreshold micropulse laser with respect to the pri-
mary outcome (BCVA in the study eye at 24months). The
trial will have sufficient statistical power to determine su-
periority of one laser treatment over the other. Further-
more, it will also have sufficient statistical power to
determine equivalence of the types of laser treatment, be-
cause it is possible that even if no differences in the pri-
mary outcome are observed between the two, there may
be differences in important secondary outcomes (e.g. pa-
tient reported outcomes (PROS)).
Based on a mean (standard deviation; SD) of 0.08
(0.23) logMAR for BCVA change from baseline for the
standard care laser [11] and a permitted maximum dif-
ference of 0.1 logMAR (5 ETDRS letters) between
groups, we estimated that DIAMONDS will require 113
randomised participants per group, at 90% power and
0.05 level of significance. Allowing for up to 15%
dropout rate during the 24 months of follow-up, as ob-
served in other randomised trials on DMO with out-
comes determined at that time point [7, 21] a total of
266 patients will be recruited.
A permitted maximal difference of 5 ETDRS letters be-
tween groups was chosen as the non-inferiority margin
because a 5 ETDRS letter or less difference is not consid-
ered clinically relevant or meaningful to patients [4, 5].
If data are available for 113 patients per group, this
will also be sufficient to detect a mean difference be-
tween lasers of 37.7 μm in CST (based on SD of 86.8
[12]) and of 6.55 in the NEI-VFQ (based on SD of 15.1
as per previous publication [22]). These are important
secondary outcomes for DIAMONDS and such differ-
ences in CST and NEI-VFQ-25 scores have both been
shown to be clinically relevant differences [23, 24].
Data analysis plan
The primary statistical analysis will be per protocol ra-
ther than an intention-to-treat (ITT) analysis. ITT ana-
lysis, which is recommended for superiority trials, will
be performed but per-protocol analysis is preferred for
non-inferiority or equivalence trials [25] because ITT in-
creases the type I error in such trials.
The difference between laser treatments for change
in BCVA (using 95% CI) from baseline to month 24
(primary endpoint) will be compared to the permitted
maximum difference of 5 ETDRS letters (0.1 logMAR).
The subthreshold micropulse laser can be deemed to
be non-inferior to the standard laser if the lower limit
Fig. 1 DIAMONDS Consolidated Standards of Reporting Trials (CONSORT) flow diagram
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of the 95% confidence interval of the treatment differ-
ence lies above the non-inferiority margin. If the 95%
confidence interval of the treatment difference lies
wholly within both the upper and lower margins of
the permitted maximum difference (+/− 5 ETDRS let-
ters), then subthreshold micropulse laser can be deemed
to be equivalent to the standard laser. Change in BCVA
from baseline to month 24 will be compared between the
two laser groups using an analysis of covariance
(ANCOVA) model adjusted for baseline BCVA score,
baseline CST and minimisation factors/covariates includ-
ing centre, distance BCVA at presentation [≥ 69 ETDRS
letters (Snellen equivalent ≥ 20/40; logMAR ≥ 0.3) or 24–
68 ETDRS letters (Snellen equivalent ≤ 20/50; logMAR
0.4–1.2)] and previous use of anti-VEGFs or laser in the
study eye. The primary analysis will be based on data from
the study eye only. When performing a secondary analysis
on the subset of subjects with both eyes treated, study eye
will be included as a random effect within the mixed
model. Statistical diagnostic methods will be used to check
for violations of the model assumptions and data transfor-
mations or non-parametric equivalents such as the Mann-
Whitney test may be performed as appropriate.
Statistical significance will be based on two-sided
tests, with P < 0.05 taken as the criterion for statistical
significance. The principal analysis will be based upon
available case data with no imputation of missing
values. Sensitivity will be analysed to assess the impact
of missing data by imputing extreme values (lowest and
highest). Additionally, the primary outcome will be ana-
lysed according to pre-specified subgroups (previous
use of anti-VEGFs or macular laser in the study eye) by
including the corresponding interaction term in the re-
gression model using stricter criteria for statistical sig-
nificance (P ≤ 0.01). Side effects of the treatment and
use of additional treatments will be analysed using lo-
gistic regression models with adjustment for the mini-
misation covariates. Health-related and visual-related
quality of life measures, secondary measures of visual
function, anatomical outcomes and number of treat-
ments required will be analysed using linear regression
models adjusted for baseline BCVA score and mini-
misation variables. “Driving ability” (meeting standards
for driving) will be analysed using a logistic regression
model adjusted for baseline BCVA and the minimisa-
tion variables.
Using random allocation and a standard care arm, we
aim to reduce regression to the mean (RTM) in the de-
sign stage and we will use ANCOVA as a secondary
analysis to account for possible effects of RTM. Base-
line characteristics, follow-up measurements and safety
data will be described graphically and in tabular format
using descriptive summary measures depending on the
scale of measurement and distribution. A detailed
statistical analysis plan (SAP) will be written by the trial
statistician prior to the final analysis.
Health economic analysis
An economic evaluation will be conducted alongside the
trial with a 2-year time horizon from a National Health Ser-
vice (NHS) and personal social services perspective to esti-
mate the cost per QALY gained of subthreshold micropulse
compared with standard threshold laser. This will take into
account utility gains from preservation or improvement in
vision, and disutilities from adverse effects, including any
effects on anxiety. Resource use of the different laser treat-
ments, including staff time, equipment required, overheads,
consumables, any rescue treatments and any other visits or
resources used due to DMO for each patient will be re-
corded on the CRFs. Unit cost information obtained from
published sources and centres participating in the trial will
be attached to each resource item in order to calculate a
cost for each trial patient. QALYs will be calculated as the
area under the baseline-adjusted utility curve, and will be
calculated using linear interpolation between baseline and
follow-up utility scores.
A Markov model will be used to extrapolate beyond the
trial, with costs and benefits discounted at 3.5%. The model
will be populated by data from the trial and supplemented
by estimates from published literature and expert opinion.
Results will be expressed as cost per QALY gained. We will
use sensitivity analyses to assess the robustness of the re-
sults, with probabilistic sensitivity analyses to explore un-
certainty in model parameters and allow the presentation
of cost-effectiveness acceptability curves.
Patient and public involvement (PPI) in DIAMONDS
A PPI group (DIAMONDS PPI) was created very early
on, at the stage of trial conception. The PPI provided in-
put on trial design and outcome measures important to
patients with DMO.
Discussion
Progress made so far (as per September 28, 2018): re-
cruitment has started at all participating sites (n = 16).
Eleven sites were originally opened to recruitment; five
others were added at a later date to ensure full recruit-
ment would be achieved in the recruitment period of the
trial. A total of 233 participants (out of the 266 required)
have been recruited into the trial.
Trial status
The current protocol is Protocol v4.0 22 November 2017.
Recruitment started on 18 January 2017. The anticipated
date of recruitment completion is 18 December 2018.
This protocol was prepared following standard proto-
col items: recommendation for interventional trials
(Additional file 1) guidelines [26]; items listed in the
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World Health organisation Trial Registration Data Set
have been specified throughout this protocol. A SPIRIT
checklist has been provided with this manuscript.
Additional files
Additional file 1: Reporting checklist for protocol of a clinical trial.
(DOCX 24 kb)
Additional file 2: Roles and responsibilities of the Trial Steering
Committee (TSC) and Data monitoring and Ethics Committee (DMEC).
(PDF 434 kb)
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